Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Tuesday

Apellis Pharmaceuticals (NASDAQ:APLS) is anticipated to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $199.2760 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $22.28 on Monday. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $30.48. The stock’s 50-day simple moving average is $23.31 and its 200 day simple moving average is $23.87. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of 71.87 and a beta of 0.26.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Caroline Baumal sold 2,797 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $60,890.69. Following the completion of the sale, the insider owned 86,527 shares of the company’s stock, valued at $1,883,692.79. The trade was a 3.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Cedric Francois sold 27,192 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $591,969.84. Following the completion of the transaction, the chief executive officer owned 286,045 shares of the company’s stock, valued at $6,227,199.65. The trade was a 8.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 120,537 shares of company stock worth $2,608,532 in the last three months. 6.80% of the stock is owned by insiders.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of APLS. Creative Planning bought a new stake in shares of Apellis Pharmaceuticals in the 2nd quarter valued at about $378,000. Acadian Asset Management LLC increased its stake in Apellis Pharmaceuticals by 1,146.2% in the 1st quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock worth $522,000 after purchasing an additional 22,052 shares during the period. Focus Partners Wealth lifted its position in Apellis Pharmaceuticals by 118.4% in the first quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock valued at $479,000 after purchasing an additional 11,862 shares during the last quarter. Bridgefront Capital LLC bought a new stake in Apellis Pharmaceuticals in the fourth quarter valued at approximately $285,000. Finally, Franklin Resources Inc. purchased a new stake in shares of Apellis Pharmaceuticals during the fourth quarter valued at approximately $284,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on APLS shares. Needham & Company LLC lowered their price target on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. The Goldman Sachs Group reiterated a “sell” rating and issued a $19.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, January 12th. Mizuho reduced their price target on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. TD Cowen decreased their price target on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Finally, Robert W. Baird lifted their price objective on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Twelve investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $33.00.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.